- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06942702
Efficacia del blocco genicolare sulla chirurgia dell'artroplastica totale del ginocchio
Assesa dell'efficacia analgesica postoperatoria del blocco genicolare applicato preoperatorio sull'artroplastica totale del ginocchio: uno studio controllato randomizzato
This prospective, randomized, double-blind, placebo-controlled trial evaluated the analgesic efficacy of preoperative ultrasound-guided genicular nerve block (GNB) in patients undergoing total knee arthroplasty.
A total of 64 patients were randomly assigned to two groups (32 patients per group). The GNB group received 5 mL of 0.25% bupivacaine at each of three genicular nerve targets, whereas the placebo group received 5 mL of 0.9% normal saline at the same anatomical targets.
All patients underwent standardized general anesthesia and received postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia.
The primary outcome was movement-evoked pain intensity, assessed using the visual analog scale (VAS) at 24 hours postoperatively. Secondary outcomes included pain scores at other postoperative time points, opioid consumption, and knee range of motion.
Participants and outcome assessors were blinded to group allocation.
Panoramica dello studio
Stato
Descrizione dettagliata
Patients scheduled for elective primary unilateral total knee arthroplasty were randomly allocated in a 1:1 ratio to the genicular nerve block (GNB) group or the placebo control group.
Approximately 30 minutes before surgery, all patients underwent an ultrasound-guided injection procedure targeting the superomedial, superolateral, and inferomedial genicular nerves.
Patients in the GNB group received 5 mL of 0.25% bupivacaine at each target (total volume: 15 mL). Patients in the placebo control group received 5 mL of 0.9% normal saline at each corresponding target (total volume: 15 mL).
The injections were performed by an anesthesiologist who was aware of group allocation and was not involved in postoperative outcome assessment. Participants and outcome assessors remained blinded to treatment allocation.
All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous paracetamol, intramuscular diclofenac, and patient-controlled intravenous morphine analgesia.
Postoperative pain intensity was assessed using the visual analog scale (VAS) at rest and during movement. The primary outcome was movement-evoked VAS at 24 hours after surgery. Secondary outcomes included other postoperative VAS measurements, morphine consumption, and knee range of motion.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Mersin
-
Mersin, Mersin, Turchia (Türkiye), 33120
- Mersin University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Scheduled for unilateral and primary total knee arthroplasty
- Older than 18 years of age
Exclusion Criteria:
- Younger than 18 years
- Bilateral knee arthroplasty
- Revision case of knee arthroplasty
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Genicular block group
Patients received preoperative ultrasound-guided genicular nerve block with 5 mL of 0.25% bupivacaine injected at each of three anatomical targets: superomedial, superolateral, and inferomedial genicular nerves (total volume: 15 mL). All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia, paracetamol, and diclofenac. |
Patients received preoperative ultrasound-guided genicular nerve block with 5 mL of 0.25% bupivacaine injected at each of three anatomical targets: superomedial, superolateral, and inferomedial genicular nerves (total volume: 15 mL). Standardized postoperative multimodal analgesia consisting of intravenous paracetamol 1 g every 8 hours and intramuscular diclofenac sodium 75 mg every 12 hours during the first 48 postoperative hours, administered to both study groups. Postoperative intravenous patient-controlled analgesia with morphine, programmed to deliver a 1 mg demand dose with a 15-minute lockout interval. The same PCA regimen was used in both study groups. |
|
Comparatore placebo: placebo
Patients received preoperative ultrasound-guided placebo injections consisting of 5 mL of 0.9% normal saline at each of the same three genicular nerve targets (total volume: 15 mL). All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia, paracetamol, and diclofenac. |
Standardized postoperative multimodal analgesia consisting of intravenous paracetamol 1 g every 8 hours and intramuscular diclofenac sodium 75 mg every 12 hours during the first 48 postoperative hours, administered to both study groups. Postoperative intravenous patient-controlled analgesia with morphine, programmed to deliver a 1 mg demand dose with a 15-minute lockout interval. The same PCA regimen was used in both study groups. Patients received preoperative ultrasound-guided placebo injections consisting of 5 mL of 0.9% normal saline at each of the same three genicular nerve targets (total volume: 15 mL). |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Visual Analog Scale Measure
Lasso di tempo: 0-48 hours
|
VAS scores are assessed at 0th, 24th and 48th hours post operatively VAS score consists of 0-10 in numbers, the bigger the number the worse the pain |
0-48 hours
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
opioid consumption
Lasso di tempo: 0-48 hours
|
Morphine consumption is assesed by PCA |
0-48 hours
|
|
Range of Motion Measurements
Lasso di tempo: 0-48 hours
|
Knee range of motion (ROM) are assessed in degrees during active knee flexion. Measurements are obtained preoperatively and at predefined postoperative time points. Higher values indicate greater knee flexion. |
0-48 hours
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Mustafa Azizoglu, Associated Professor, Mersin university Faculty of Medicine, Department of Anesthesiology and Reanimation
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Dolore
- Manifestazioni neurologiche
- Complicanze postoperatorie
- Processi patologici
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Dolore, Postoperatorio
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, anello fuso
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Alcaloidi
- Idrocarburi policiclici aromatici
- Composti policiclici
- Anilides
- Amides
- Composti di anilina
- Ammine
- Acetanilides
- Prodotti chimici inorganici
- Composti di cloro
- Composti eterociclici, 4 o più anelli
- Morfinani
- Alcaloidi oppiati
- Composti eterociclici, anello a ponte
- Fenantreni
- Tecniche immunologiche
- Derivati della morfina
- Composti di sodio
- Test immunologici
- Cloruri
- Acido cloridrico
- Test cutanei
- Fenomeni del sistema immunitario
- Reazioni antigene-anticorpi
- Acetaminofene
- Morfina
- Cloruro di sodio
- Anafilassi cutanea passiva
Altri numeri di identificazione dello studio
- MersinUgenicular
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .